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a b s t r a c t
Enhancing protein stability upon encapsulation and release from polymers is a key issue in sustained release
applications. In addition, optimum drug dispersion in the polymer particles is critical for achieving release
proﬁles with low unwanted initial “burst” release. Herein, we address both issues by formulating the model
enzyme α-chymotrypsin (α-CT) as nanoparticles to improve drug dispersion and by covalently modifying
it with glycans to afford improved stability during encapsulation in poly(lactic-co-glycolic) acid (PLGA)
microspheres. α-CT was chemically modiﬁed with activated lactose (500Da) to achieve molar ratios of
4.5 and 7.1 lactose-to-protein. The bioconjugates were co-lyophilized with methyl-β-cyclodextrin followed
by suspension in ethyl acetate to afford nanoparticles. Nanoparticle formation did not signiﬁcantly impact
protein stability; less than 5% of the protein was aggregated and the residual activity remained above 90%
for all formulations. Using a solid-in-oil-in-water (s/o/w) methodology developed in our laboratory for
nanoparticles, we obtained amaximum encapsulation efﬁciency of 61%. Glycosylation completely prevented
otherwise substantial protein aggregation andactivity loss during encapsulationof thenon-modiﬁedenzyme.
Moreover, in vitro protein release was improved for glycosylated formulations. These results highlight the
potential of chemical glycosylation to improve the stability of pharmaceutical proteins in sustained release
applications.
c© 2012 Elsevier B.V. All rights reserved.
1. Introduction
The sustained release of pharmaceutical proteins frompoly(lactic-
co-glycolic)acid (PLGA)microspheres for prevention and treatment of
diseases has received wide interest [1–5]. Still, the encapsulation of
proteins in the necessarily quite hydrophobic polymer matrix has re-
mained challenging because the polymer is mostly dissolved in an
organic solvent. Proteins are chemically and physically fragile and
are susceptible tomechanical, thermal, and chemical stresses encoun-
tered in theencapsulationprocess. In thisworkwe focuson improving
physical instability issues during encapsulation which are character-
ized by protein structural changes potentially leading to subsequent
irreversible inactivation and aggregation.
The most commonly employed polymer in sustained release ap-
plications of proteins is the family of PLGA co-polymers [6].Water-in-
oil-in-water (w/o/w), solid-in-oil-in-water (s/o/w), and solid-in-oil-
in-oil (s/o/o) encapsulation are the most commonly used methods
to incorporate proteins into PLGA microspheres [7]. The s/o/w en-
capsulation methods are advantageous when working with proteins
because they avoid the ﬁrst w/o interface encountered in w/o/w en-
capsulation which is particularly detrimental to protein integrity [4]
and do not involve the use of an excess of organic solvent as in the s/
* Corresponding author. Tel.: +1 787 764 0000x7374; fax: +1 787 756 8242.
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o/omethods [8]. Unfortunately, also s/o/wencapsulation procedures
are not free of protein stability issues likely due to the increased struc-
tural dynamics (ﬂexibility) of the protein upon rehydration in the
oil-in-water emulsion step [9]. Furthermore, the release of proteins
from PLGA devices also produces difﬁculties, such as, protein instabil-
ity due to exposure to PLGA hydrolysis products, high initial “burst”
release, and incomplete protein release [5,10]. Protein aggregates are
frequently formed during encapsulation and release and this must be
avoided because they can cause dangerous immune reactions [9,11].
It has to be pointed out, however, that no maximum aggregate levels
have been deﬁned by the US Food and Drug Administration (FDA) and
they should, in general, be kept as low as possible.
Some researchhasbeenperformed focusingoneradicatingprotein
aggregation and inactivation during the harsh encapsulation proce-
dures and during release caused by PLGA-degradation produced acid-
iﬁcation [1,7,12,13]. However, protein inactivation, aggregation, and
unfolding during encapsulation are still issues severely hampering
the application of sustained protein release PLGA microparticles [9].
To tackle protein stability problems during encapsulation in PLGA
microspheres we engaged in a dual approach. First, we employed
protein powders formulated as nanoparticles in a s/o/w encapsula-
tion procedure. Drug particle size is highly relevant in this context
because it can inﬂuence the bioavailability, loading, release, and sta-
bility of the drug. In s/o/w/ encapsulation reduced protein particle
size shouldafford improveddrugdispersion in thePLGAmicrospheres
2211-2863/$ - see front matter c© 2012 Elsevier B.V. All rights reserved.
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and improved release [14–16]. Second, we performed chemical gly-
cosylation to improve thermodynamic and colloidal stability of our
modelprotein. Covalent chemicalmodiﬁcation (which includesmodi-
ﬁcation with poly(ethylene glycol), carbohydrates, and cross-linking)
is a promising approach to enhance protein stability in industrial
and pharmaceutical applications [17–20]. The chemical glycosylation
as performed by our laboratory consists in the modiﬁcation of one
or more protein lysine residues with chemically activated glycans
[17,21]. Sola´ and Griebenow [22] demonstrated that increasing the
size andamountof chemically attachedglycansdidnot alter the struc-
ture of α-chymotrypsin (α-CT) employed as model enzyme herein
but that a substantial decrease in protein structural dynamics and in-
crease in stability was induced by glycosylation. Similar ﬁndings have
also been reported by us for subtilisin Carlsberg [21].
In this study, we encapsulated glycosylated α-CT powders for-
mulated as nanoparticles in PLGA microspheres by a s/o/w method.
Protein stability was assessed as a function of the amount of bound
lactose.
2. Materials and methods
2.1. Materials
α-Chymotrypsin (EC 3.4.21.1, type II from bovine pancreas),
poly(vinyl) alcohol (87%–89% hydrolyzed, MW of 13,000–23,000),
and methyl-β-cyclodextrin (MβCD) were purchased from Sigma-
Aldrich (St. Louis, MO). Succinyl-Ala-Ala-Pro-Phe-p-nitroanilide was
fromBachem(Kingof Prussia, PA) andpoly(d,l -lactic-co-glycolic)acid
(PLGA) with a copolymer ratio of 50:50 and an averageMW of 10,000
was from Lakeshore Biomaterials (Resomer RG502H, lot 260187, not
endcapped). All other chemicals were from various suppliers and the
purity of analytical grade or better.
2.2. Synthesis of α-CT glycoconjugates
Covalent modiﬁcation of α-CT with lactose was performed as de-
scribed in detail by Sola´ and Griebenow [22]. In brief, to attach vari-
ous amounts of lactose to the enzyme, different amounts of activated
lactose were added to a α-CT solution (4.5 and 7.1mol of reagent
per mol of protein) in 0.1M borate buffer, pH 9.0 and stirred at 4 ◦C
for 2h. The glycoconjugates obtained were lyophilized and stored at
−20 ◦C until further use. The degree of protein modiﬁcation was de-
termined by colorimetric titration of unreacted amino groups with
2,4,6-trinitrobenzene sulfonic acid (TNBSA) [23].
2.3. Preparation of conjugate nanoparticles
Formulation ofα-CT as nanoparticles was performed as described
in detail by Montalvo et al. [24]. In brief, α-CT and the lactose conju-
gateswere dissolved in deionizedwater at 40mg/mLprotein concen-
tration andmethyl-β-cyclodextrin co-dissolved to achieve a 1:4mass
ratio of protein-to-cyclodextrin. These samples were lyophilized for
48h and stored at −20 ◦C [23].
Protein nanoparticles were formed by suspending the lyophilized
powders in 40mL of ethyl acetate [24]. This suspensionwas sonicated
for 30 s in an ultrasonic cleaning bath and the nanoparticles collected
by centrifugation for 10min at 7000 rpm and 4 ◦C in a Hermle Z 323K
with a Hermle Rotor # 220.80V02 from Labnet Int. (Woodbridge, NJ).
2.4. PLGA microsphere preparation
Microsphere preparation by a s/o/w encapsulation procedure fol-
lowed the protocol developed by Griebenow and co-workers [25]. In
brief, 40mg of lyophilized α-CT powder or nanoparticles were sus-
pended in 2mL of ethyl acetate containing 360mg of PLGA by homog-
enization with a VirTis Tempest using a 10-mm shaft (40,000 rpm,
30 s). This suspension was poured into 50mL of PVA (10% w/v in
distilled water) and the solid-in-oil-in-water emulsion was formed
by homogenization (40,000 rpm, 2min). Microspheres formed under
stirring for 3h. They were collected by ﬁltration through a 0.45μm
pore size cellulose acetate ﬁlter, washed with 100mL of distilled wa-
ter, and dried for 24h under a vacuum of <60 μm of Hg.
2.5. Determination of protein loading and encapsulation efﬁciency
The encapsulation efﬁciency was determined as described by us
[8]. In brief, 20mg of PLGA microspheres were dissolved in 2mL
of ethyl acetate and stirred for 2h, followed by centrifugation at
9000 rpm for 10min. The supernatant was discarded and the pel-
let vacuum dried for 30min. The mostly of protein consisting pellet
was dissolved in 2mL of phosphate buffer. To separate the soluble
and insoluble protein fractions, the samples were subjected to cen-
trifugation at 9000 rpm for 10min; the soluble fraction was removed
and 1mL of 6M urea was added to the buffer insoluble-fraction to
completely dissolve the protein aggregates. The protein concentra-
tion was determined by measuring the UV absorbance at 280nm and
by BCA assay at 562nm. The encapsulation efﬁciency of protein in the
microspheres was calculated from the actual loading with respect to
the theoretical loading of protein (%w/w) in the microspheres. The
experiments were performed in triplicate and the results averaged
and the standard deviations calculated.
2.6. Determination of enzyme activity
Activity ofα-CT was determined using succinyl-Ala-Ala-Pro-Phe-
p-nitroanilide as the substrate. The reactionwas carried out in 1mL of
0.1M Tris–HCl buffer containing 0.6mg enzyme (protein), 0.35mM
substrate, and 0.01M CaCl2 at pH 7.8. To determine the activity of
α-CT after encapsulation ethyl acetate was used to dissolve PLGA
because it does not cause enzyme inactivation in the process [13]. The
experiments were performed in triplicate and the results averaged.
Error bars in the ﬁgures are the calculated standard deviations.
2.7. Scanning Electron Microscopy (SEM)
SEM of α-CT nanoparticles, PLGA microspheres, and lyophilized
protein powder was performed using a JEOL 5800LV scanning elec-
tron microscope at a voltage of 20 kV. The samples were coated with
gold (200–500 A˚ thickness). For each sample, the diameter of 100mi-
crospheres was determined from images, averaged, and the standard
deviation calculated.
2.8. Dynamic light scattering
Dynamic light scattering was performed using a DynaPro Titan
with Ambient MicroSampler from Wyatt Technology Corporation
(Santa Barbara, CA). Protein suspensions in ethyl acetate were added
to the cell and measured at 100% power intensity. The data analysis
was done using the Dynamic 6.7.6 software.
2.9. In vitro release studies
Microspheres (30mg)were incubated in 1mLof 10mMphosphate
buffer at pH 5.0 containing 0.05% sodium azide to prevent microbial
growth and incubated at 37 ◦C [13]. At predetermined times the sam-
ples were subjected to centrifugation (5000 rpm for 5min) to pellet
the insoluble components. The supernatant was removed, the con-
centration of released protein determined, and the buffer replaced.
Protein concentration was determined from the UV absorption at
280nm and the small contribution due to eroding microspheres sub-
tracted. For this purpose blank microspheres were subjected to in
vitro release conditions [8,9].
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2.10. FTIR spectroscopy
FTIR studies were conducted using a Nicolet NEXUS 470 optical
bench as described in detail by us [26–29]. When necessary, the
respective backgrounds were subtracted from the spectra acquired.
Spectrawere analyzed in the amide I spectra region as described by us
including band assignment inGaussian curve-ﬁtting analysis [26–29].
2.11. Statistical methods
Statistical analysis was performed using Minitab 14 (Minitab Inc.,
State College, PA) software. The Dunn’s test was applied to means
of individual data statistical signiﬁcance was accepted at the p ≤
0.05 level. The results presented in this work are the averages of at
least three measurements and standard deviations were calculated
for those data.
3. Results and discussion
3.1. Effect of glycosylation on α-chymotrypsin stability during s/o/w
encapsulation
During s/o/w encapsulation proteins are exposed to an organic
solvent/water interface which can cause protein structural pertur-
bations and aggregation [2,9,29]. Even though protein powders are
initially suspended in an organic solvent, during the o/w step of the
procedure partial rehydration of protein particles will occur. This will
increase protein conformational mobility and expose it to the dena-
turing stress imposed by the organic solvent [11,30,31].
In order to overcome these problems, herein we explore the gly-
cosylation of the model enzyme α-CT to increase its stability during
the encapsulation procedure. It has been previously demonstrated
by us that the covalent chemical modiﬁcation of α-CT and subtilisin
Carlsberg with glycans is one of the most promising techniques to in-
crease their stability since glycan–protein interactions lead to shield-
ing of the protein surface from water thus restricting conformational
motions [17,19–21]. Moreover, we also aimed at developing a drug
delivery system with a relatively low burst release and improve the
encapsulation efﬁciency. Our approach to reach this particular goal
was to formulate the glycoconjugates as nanoparticles.
α-CT was chosen as themodel protein since it has been employed
previously by us to study the effect of glycosylation on enzyme stabil-
ity including in the solid phase [17,18,21,22] and has been formulated
as solid nanoparticles by us [24]. In addition,α-CT is an excellent sen-
sor for encapsulation-induced aggregation and inactivation and has
been employed by us frequently as model enzyme in s/o/w encapsu-
lation procedures [13,29].
Lactose was covalently attached to α-CT using synthesis condi-
tions adjusted to achieve an average number of lactose molecules
bound to the protein of 4 (Lac4-α-CT) and 7 (Lac7-α-CT) since max-
imum thermodynamic and colloidal stability in solution have been
reported for these constructs [18,22].
3.2. Protein nanoparticle preparation and characterization
To test whether we could form nanoparticles using the neo-
glycoconjugates, we co-dissolved α-CT and the α-CT glycoconju-
gates with methyl-β-cyclodextrin at a 1:4 mass ratio followed by
lyophilization and suspension of the dry powders in ethyl acetate. The
particles obtained were subjected to centrifugation and collected as
described [24]. SEM images ofα-CT lyophilized without MβCD show
that the powder particles had an irregular shape and the particle size
was in the micrometer range (Fig. 1A). In contrast, co-lyophilization
with MβCD followed by suspension in ethyl acetate caused a dras-
tic reduction in particle size for all formulations. α-CT nanospheres
had a diameter of 115±5nm (Fig. 1B), Lac4-α-CT nanospheres one of
Fig. 1. SEMmicrographs of lyophilized α-CT (A) and of nanoparticles formed using
(B) α-CT, (C) Lac4-α-CT, and (D) Lac7-α-CT.
Table 1









α-CT 2 ± 1 100 ± 2 115 ± 5
Lac4-α-CT 5 ± 0 100 ± 2 248 ± 11
Lac7-α-CT 3 ± 2 90 ± 2 261 ± 4
Table 2













α-CT 30 ± 1 24 ± 2 53 ± 5 10–61
Lac4-α-CT 61 ± 1 2 ± 1 100 ± 1 3–130
Lac7-α-CT 23 ± 2 8 ± 2 84 ± 2 2–55
a Encapsulation efﬁciency is the percentage of encapsulated protein compared to the
theoretical loading.
b Aggregated α-CT is the percentage with respect to the total amount of encapsulated
protein.
c The activity (%) is the residual activity of α-CT released from PLGA microspheres.
d The microsphere diameter was obtained by analyzing SEM images.
248±11nm (Fig. 1C), and Lac7-α-CT nanospheres one of 261±4nm
(Fig. 1D) as determined by dynamic light scattering (Table 1). It was
noticeable that the diameter of the particles approximately doubled
as a consequence of the glycosylation. Nanoparticle formation did not
compromise protein stability. The formation of buffer-insoluble pro-
tein aggregates was ≤5% for all the samples regardless of the mod-
iﬁcation. Furthermore, the residual activity of the samples did not
change with exception of Lac7-α-CT for which a 10% drop occurred
(Table 1). All samples were subsequently employed to test the stabil-
ity consequences of their encapsulation in PLGA microspheres.
3.3. Encapsulation of protein nanoparticles into PLGA microspheres.
Microspheres were prepared by a s/o/w technique using α-CT
nanoparticles (Table 2). The encapsulation efﬁciency was between
23 and 61% allowing us to perform subsequent stability and release
studies.
Protein stability during encapsulation in the PLGA microspheres
was markedly improved by glycosylation. The amount of non-
covalent buffer-insoluble aggregates formed during encapsulation
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was 24% for the non-modiﬁedα-CT formulated as nanoparticles (Ta-
ble 2) which is comparable to 18% reported for lyophilized α-CT
[2,12]. A substantial reduction was noted for the encapsulated gly-
coconjugates: only 2% aggregates were found for encapsulated Lac4-
α-CT bound and 8% for Lac7-α-CT. Reduction in aggregation has been
attributed to the role of the glycans as spacer molecules preventing
interactions of unfolded proteins [19,20].
Next, the effect of the nature of the glycosylation and nanoparti-
cle formation on the morphology ofα-CT-loaded PLGAmicrospheres
was investigated. Encapsulation of all formulations produced micro-
spheres with a spherical shape and smooth surface (Fig. 2A–C). The
most signiﬁcant difference between the different formulations was
the size of the microspheres (Table 2). Microspheres with widely
varying sizes were observed for all formulations (Table 2). An in-
creasing amount of glycosylation of the enzyme (Lac7-α-CT) caused
a signiﬁcant reduction in the size of the microspheres (Fig. 2C) which
could be a reason for the low encapsulation efﬁciency observed for
this preparation.
3.4. Activity of α-CT after encapsulation in PLGA microspheres
The residual α-CT activity was determined for the different for-
mulations after encapsulation in PLGA microspheres. As a control,
the residual activity for the different glycosylated formulations was
determined prior to encapsulation to ascertain that the inactivation
observed was caused by the encapsulation process and not by the
initial lyophilization or nanoparticle formation step (Table 1). All gly-
cosylated formulations exhibited higherα-CT activities than the non-
glycosylatedα-CT after encapsulation into PLGAmicrospheres (Table
2). The non-glycosylated nanoparticulate sample had a residual ac-
tivity of 53±5% after encapsulation which is comparable to 53±8%
found upon s/o/w encapsulation of lyophilized α-CT powder [12].
This demonstrates that the different mode of dehydration and for-
mulation prior to encapsulation had no inﬂuence on enzyme stability
while glycosylation caused amarked improvement of stability during
encapsulation.
We assume that inactivation during encapsulation mainly stems
from exposure of α-CT to the organic solvent in the presence of wa-
ter. During encapsulation, speciﬁcally during formation of the o/w
emulsion water enters the organic solvent phase andwill hydrate the
protein [29]. Such hydration results in increased protein structural
mobility thus making it more amenable to irreversible unfolding and
thus inactivation [2,19,20]. One can hypothesize that decreased con-
formational mobility as the result of glycosylation should counter
such events [17,21,22]. Glycosylation indeed had a signiﬁcant effect
on preserving enzyme activity upon encapsulation. Remarkably, for
Lac4-α-CTwe found complete retention of the activity upon encapsu-
lation and for Lac7-α-CT residual activity was >50% higher (84±2%)
than for the non-glycosylated protein. In summary, our data show
that α-CT glycosylation leads to a remarkable increase of its stability
upon s/o/w encapsulation in PLGA microspheres. These ﬁndings will
have to be veriﬁed with another protein to establish whether this is
a general phenomenon as we assume or protein speciﬁc.
3.5. Secondary structure of α-CT during the S/O/W encapsulation
process
To investigate the potential mechanism of structural stabilization
by glycosylation observed during encapsulation, we investigated the
secondary structure of α-CT and the glycoconjugates encapsulated
in PLGA microspheres by Fourier-transform infrared (FTIR) spec-
troscopy. In principal, glycosylation could afford structural preserva-
tionupon lyophilization and encapsulation (similar to lyoprotectants)
[19] or simply work as molecular spacer keeping unfolded molecules
Fig. 2. SEMmicrographs of PLGA microspheres with encapsulated (A) α-CT, (B)
Lac4-α-CT, and (C) Lac7-α-CT.
apart and thus prevent aggregation and inactivation [18,22]. Two sim-
ilar states of the samples were compared; nanoparticles before en-
capsulation and after the complete encapsulation process. The struc-
turally sensitive amide I band (1600–1700 cm−1) was utilized and
subjected to a Gaussian curve-ﬁtting procedure to extract the sec-
ondary structure composition [28].
α-CT secondary structure in aqueous solution is dominated byβ-
sheet structure (Table 3). Lyophilization leads to an apparent increase
in the α-helix content and insigniﬁcant changes in the β-sheet con-
tent [32,33]. In contrast, a signiﬁcant loss in β-sheet structure was
foundupon formulation as nanoparticleswhile encapsulation in PLGA
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Table 3
Secondary structure composition of α-chymotrypsin under different conditions.
Sample/condition α-helixa (%) β-sheet (%)
α-CT
Aqueous solution 14 ± 2 40 ± 2
Lyophilized powder 17 ± 2 41 ± 5
Nanoparticle 17 ± 2 29 ± 2
Nanoparticle in PLGA
microspheres








17 ± 2 60 ± 2
a Unordered andα-helix secondary structure amide I IR bands overlap strongly inα-CT
which causes an apparent increase in the α-helix content upon lyophilization.
microspheres did not causemajor additional structural changes. Sim-
ilar results were reported byMontalvo et al. [24] forα-CT, suggesting
that this loss inβ-sheet structure is mainly caused by the nanoparti-
cle formulation and not by the encapsulation step.
Attachment of four lactose molecules to the enzyme caused no
spectral and thus structural alterations compared to thenon-modiﬁed
protein, while attachment of seven lactose molecules caused a sub-
stantial increase in theβ-sheet content. These results clearly demon-
strate that the reduction in aggregation and inactivation upon en-
capsulation (Table 2) for the glycoconjugates is not being caused by a
lyoprotectant effect of the attached lactosemolecules. Thus, it is likely
that the beneﬁcial stability increase is being caused by the spacer ef-
fect afforded by the lactose molecules keeping molecules apart. For
Lac7-α-CT it seems that the stability increase afforded by this ef-
fect is partially ameliorated by structural changes upon dehydration.
Stability and FTIR data agree in that Lac4-α-CT is the most stable
formulation.
3.6. In vitro release studies
Proteins are released from PLGA microspheres ﬁrst by polymer
swelling and diffusion and then also by polymer erosion. One of the
main challenges of the development of a sustained release system
based on polymer microspheres is minimizing the initial “burst” re-
lease [9,34,35]. One reason for burst release after s/o/w encapsula-
tion is that protein particles are close to the microsphere surface and
solvent enters the polymer through small pores of the polymer ma-
trix dissolving solvent accessible protein. For example, it has been
demonstrated that microspheres showing high burst release have a
more porous surface than those with low burst release [36].
In vitro release studies were conducted investigating the magni-
tude of burst release from PLGA microspheres containing encapsu-
lated nanoparticles compared to conventional lyophilized powder.
The cumulative release proﬁles of microspheres loaded with α-CT
nanoparticles and glycosylated α-CT nanoparticles are shown in Fig.
3. Microspheres loaded with α-CT nanoparticles showed a burst re-
lease of 30% during the ﬁrst 24h which is lower than the 50% burst
release reported by us for the lyophilized powder using the same
encapsulation conditions [12]. Lyophilized protein powders typically
produce much larger protein particles in the ﬁrst s/o encapsulation
step of micrometer dimensions. This leads to a substantial burst re-
lease when microspheres are produced by a s/o/wmethodology and
has hampered practical development thus far [9,37]. Encapsulated
nanoparticles of Lac4-α-CT and Lac7-α-CT showed an even further
reduced burst release of 20% and 17%, respectively (Table 2). Our
data demonstrate that the burst release was reduced by employing
nanoparticulate protein powders.
A triphasic in vitro release of α-CT from PLGA microspheres was
observed for all formulations; the initial burst releasewas followedby
Fig. 3. Cumulative in vitro release of (Δ)α-CT, () Lac4-α-CT, and (•) Lac7-α-CT from
PLGA microspheres.
Table 4
Residual activity of α-CT-lactose conjugate after various times of in vitro release from
PLGA microspheres.
Time (h) α-CT Lac4-α-CT Lac7-α-CT
24 45 ± 2 46 ± 2 40 ± 2
48 31 ± 1 38 ± 2 43 ± 4
72 n.a. 17 ± 1 24 ± 1
96 n.a. 18 ± 1 n.a.
n.a.: no measurable activity.
a lag phase and a period of sustained release (Fig. 3). The release pro-
ﬁles were similar for all formulations employing nanoparticles with
the exception that the releasewasmore complete for the glycosylated
formulations.
The relative activity of α-CT released from microspheres was fol-
lowed for 1 week. Table 4 shows that the non-glycosylated α-CT
maintained activity only for the ﬁrst 48h. In contrast, Lac4-α-CT re-
tained 18% of its activity for 96h and Lac7-α-CT 24% of activity for
72h. Glycosylation of α-CT afforded some but only incomplete pro-
tection of the activity upon in vitro release.α-CT is inactivated during
prolonged incubation at 37 ◦C due to fragmentation and glycosylation
does not protect against that [13].
4. Conclusions
In this work we investigated whether glycosylation of the model
enzyme α-CT could be used to improve protein stability upon en-
capsulation into PLGA microspheres. α-CT was chemically modi-
ﬁed with activated lactose to achieve molar ratios of 4.5 and 7.1
lactose-to-protein and formulated as spherical nanoparticles of about
250nmdiameter. Non-modiﬁed and glycosylatedα-CT nanoparticles
were subsequently encapsulated in PLGA microspheres using a s/o/
wmethodology. We found that glycosylation was able to completely
prevent otherwise substantial protein aggregation and activity loss
during encapsulation. These results highlight the potential of chemi-
cal glycosylation to improve the stability of pharmaceutical proteins
in sustained release applications.
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